ReviewBiomarker research2017
Update on the first-line treatment for
Review in Biomarker research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 39 citations in OpenAlex.
- Anti-urease therapy: a targeted approach to mitigating antibiotic resistance in Helicobacter pylori while preserving the gut microflora.Gut pathogens · 2025Review
- Vitamin B6 inhibits activity ofJournal of enzyme inhibition and medicinal chemistry · 2024Article
- Article
- Glycyrrhizin, an inhibitor of HMGB1 induces autolysosomal degradation function and inhibits Helicobacter pylori infection.Molecular medicine (Cambridge, Mass.) · 2023Article
- Current guidelines forWorld journal of clinical cases · 2022Review
- Update on the first-line treatment ofTherapeutic advances in gastroenterology · 2022Review
- Detection of clarithromycin resistance and 23SrRNA point mutations in clinical isolates ofSaudi journal of biological sciences · 2022Article
- Extra virgin olive oil inhibitsFrontiers in microbiology · 2022Article
- A comprehensive method for determining cellular uptake of purine nucleoside phosphorylase and adenylosuccinate synthetase inhibitors by H. pylori.Applied microbiology and biotechnology · 2021Article
- A Comparison between 10-day and 12-day Concomitant Regimens forMiddle East journal of digestive diseases · 2020Article
- Reverse hybrid therapy achieves a similar eradication rate as standard hybrid therapy for Helicobacter pylori infection.Journal of the Chinese Medical Association : JCMA · 2020Article
- Synthesis, Urease Inhibition and Molecular Modelling Studies of Novel Derivatives of the Naturally Occurring β-Amyrenone.Natural products and bioprospecting · 2019Article
- Validation of a Blood Biomarker for Identification of Individuals at High Risk for Gastric Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018Article
- Article
- A Randomized Clinical Trial Comparing Triple Therapy versus Non-bismuth based Quadruple Therapy for the Eradication ofJournal of global infectious diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Because the prevalence of antibiotic resistance markedly increases with time worldwide, anti-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.